Related Experiment Video
Updated: May 17, 2025
Intralymphatic Immunotherapy and Vaccination in Mice
Published on: February 2, 2014
Active Substances from the Micro-Immunotherapy Medicine 2LC1® Show In Vitro Anti-Cancer Properties in Colon,
Camille Jacques1, Irene Marchesi2, Francesco Paolo Fiorentino2
1Preclinical Research Department, Labo'life France, Pescalis-Les Magnys, 79320 Moncoutant-sur-Sevre, France.
Abstract:
Tumor-associated macrophages (TAMs) play a pivotal role in cancer regulation by influencing tumor growth, metastasis, and the immune microenvironment. By providing low doses and ultra-low doses (ULD) of immune regulators to the organism, micro-immunotherapy (MI) medicines (MIM) could be seen as valuable adjuvant drugs in the context of a wide range of pathological conditions, including cancers. Thus, these MIM could target TAMs, affecting their phenotype and activities. In this study, the anti-tumor and the immune-stimulatory effects of four capsules out of the ten composing the Labo'life's MIM 2LC1® (2LC1-1, 2LC1-6, 2LC1-7, and 2LC1-8), as well as the specific nucleic acid (SNA®) sequence SNA-MYC present at ULD in this medicine have been evaluated in vitro, in several cancer models, and in human monocyte-derived macrophages. Our results showed that the tested MI formulations increased the tumor cell death of spheroids from HCT-116 colon cancer cells, while reducing the spheroid volume. Moreover, the treatments impaired the clonogenic capabilities of two cancer cell lines from epithelial origin, the LNCaP prostate cancer and the MCF-7 breast cancer cells. Interestingly, ULD of the SNA-MYC shared similar anti-cancer capabilities in those models, and it led to a significant reduction in the expression of C-MYC when evaluated in a model of human M2 macrophages. In the same model, the MI formulations also increased the expression of CD86 and HLA-DR, two markers of M1 anti-tumor macrophages. In addition, the tested items modulated the secretion of a panel of chemokines related to macrophage activity and immune cell recruitment. Finally, our results showed that 2LC1-8 increased the phagocytosis capabilities of human monocyte-derived macrophages, thus possibly contributing to sustaining the immune functions of M1, which are crucial in the context of cancer. Even if more research is needed to uncover their exact mechanism of action, these results suggest that the tested capsules of 2LC1 as well as ULD of SNA-MYC display both anti-tumor and immune-enhancing effects.
Insights
Micro-immunotherapy (MI) medicines (MIM) show anti-tumor effects by reducing cancer cell growth and enhancing immune responses. These MI formulations and SNA-MYC target tumor-associated macrophages (TAMs), boosting anti-cancer immunity.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Tumor-associated macrophages (TAMs) are key regulators of tumor growth, metastasis, and the immune microenvironment.
- Micro-immunotherapy medicines (MIM), utilizing low and ultra-low doses (ULD) of immune regulators, are explored as adjuvant therapies for cancer.
- MIM may target TAMs, influencing their phenotype and anti-tumor activities.
Purpose of the Study:
- To evaluate the anti-tumor and immune-stimulatory effects of specific MIM 2LC1 capsules and SNA-MYC.
- To investigate the impact of these agents on cancer cell lines and human monocyte-derived macrophages, particularly TAMs.
Main Methods:
- In vitro evaluation of four MIM 2LC1 capsules (2LC1-1, 2LC1-6, 2LC1-7, 2LC1-8) and SNA-MYC at ULD.
- Testing on cancer cell lines (HCT-116, LNCaP, MCF-7) and human monocyte-derived macrophages (M2 and M1 models).
- Assessment of tumor cell death, spheroid volume, clonogenic potential, C-MYC expression, M1 macrophage markers (CD86, HLA-DR), chemokine secretion, and phagocytosis.
Main Results:
- MI formulations reduced HCT-116 colon cancer spheroid volume and increased cell death.
- Treatments impaired clonogenic capabilities of LNCaP prostate and MCF-7 breast cancer cells.
- ULD SNA-MYC and MI formulations modulated M2 and M1 macrophage markers, chemokine secretion, and macrophage phagocytosis, indicating immune-stimulatory effects.
Conclusions:
- The tested MIM 2LC1 capsules and ULD SNA-MYC demonstrate significant anti-tumor and immune-enhancing effects in vitro.
- These agents show potential in modulating TAMs and boosting anti-cancer immune responses.
- Further research is warranted to elucidate the precise mechanisms of action for these micro-immunotherapy agents.
More Related Videos
Related Concept Videos
01:27Tumor Immunotherapy
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
01:40Cell-mediated Immune Responses